MoMe® Kardia delivers on the full promise of full disclosure. See How at HRS 2019.

Demo MoMe® Kardia at BIOTRONIK Booth #219 and learn how you can gain a virtual telemetry station for MCT monitoring, anywhere.

Schedule an On-Site Demo

mome device

Yes, true MCT does exist. See it for yourself at HRS Booth #219. We’ll show you why MoMe® Kardia is the only system that brings the 24/7 data and compliance benefits of inpatient telemetry to ambulatory cardiac monitoring.

New opportunities to
Speed decision-making and diagnosis

See how we deliver 24/7 telemetry data so you can look beyond reported events to verify episodes, correlate symptoms to rhythms, review onset and offset data, and in turn improve time to appropriate clinical diagnosis.

Did you know?
Even MCT service providers that say they are full disclosure only show you (or even review) data from periods of detected events.

mct report todaymct report with mome


Click to see what full disclosure really looks like

New opportunities to
Enhance the Patient Experience

See how we remove the redundancies that 3rd party service providers create, to simplify monitoring for patients and streamline management for practices.

schedule an on-site demo



Click to see the workflow of the future

Schedule a One-on-One Demo at HRS

Want to see more? Sign up for a personalized demo and practice evaluation while on-site at HRS.

    What day(s) are best for you to meet?

    Wednesday, May 8
    Friday, May 10

    Thursday, May 9
    Saturday, May 11

    infobionic logo

    321 Billerica Road
    OfficeLink #5
    Chelmsford, MA 01824

    978.674.8304 |

    Copyright © 2024 Infobionic, All Rights Reserved.


    InfoBionic's MoMe® System may be covered under one or more of the following United States Patents: 8,478,418; 8,620,418; 8,744,561; 8,774,932; 8,798,734; 9,081,884; 9,307,914; 9,307,922; 9,968,274; 10,796,552; 10,595,737; 10,376,172; 10,332,379; 10,327,657; 10,297,132; 10,282,963 and 16/409,951. This website is provided to satisfy the virtual patent marking provisions of various jurisdictions including the America Invents Act and 35 U.S.C. § 287(a). Additional patents may be issued or pending in the US and elsewhere